Company profile: Viome Life Sciences
1.1 - Company Overview
Company description
- Provider of scientific discovery, research, and development services for health and chronic disease, offering RNA-based consumer analyses for health insights and precision nutrition, and advancing prediction, precision diagnostics, and therapeutics for chronic diseases, cancer, and aging, with RNA sequencing tests including gut microbiome, human gene expression, saliva, and vaginal.
Products and services
- Viome Health Sciences: Research-driven initiative advancing prediction, precision diagnostics, and therapeutics for chronic diseases, cancer, and aging through scientific discovery and development
- Viome Consumer Services: RNA-transcriptomics-based service that analyzes gene expressions to deliver individualized health insights and precision nutrition recommendations
- Gut Microbiome Test: RNA-sequencing-based stool assay that identifies and quantifies all living microorganisms in the sample
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Viome Life Sciences
BioMark Diagnostics
HQ: Canada
Website
- Description: Provider of oncology-focused metabolomics-based cancer detection solutions, including a liquid biopsy metabolic panel for early lung cancer diagnosis using urine and plasma, a non-invasive SSAT1 assay leveraging an FDA-approved drug to detect elevated enzyme levels in cancers, a metabolomics-driven detection platform, lung cancer early detection studies, and cancer education videos.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioMark Diagnostics company profile →
RefleXion
HQ: United States
Website
- Description: Provider of biologically-guided radiotherapy systems for patients with cancer, offering SCINTIX therapy that uses emissions from cancer cells to target and treat lung or bone tumors at any stage. Provides the RefleXion X1 platform delivering SCINTIX and CT-guided IMRT and SBRT with fan-beam kVCT imaging for superior patient localization, plus Limbus Contour integration to expedite radiotherapy planning.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full RefleXion company profile →
Photocure
HQ: United States
Website
- Description: Provider of photodynamic specialty pharmaceuticals, including Hexvix/Cysview to improve bladder tumor detection and resection via Blue Light Cystoscopy, and Cevira, a photodynamic drug-device for non-surgical treatment of cervical HSIL; also supports patient registries and real-world evidence in bladder cancer. Norwegian-based.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Photocure company profile →
Synimmune
HQ: Germany
Website
- Description: Provider of innovative mono- and bispecific anti-tumor antibodies for treating life-threatening diseases, focusing on orphan hematopoietic malignancies; lead product candidate is the antibody FLYSYN.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Synimmune company profile →
Rain Oncology
HQ: United States
Website
- Description: Provider of precision oncology therapies targeting oncogenic drivers, developing milademetan, an oral small molecule inhibitor of the p53-MDM2 complex for various cancers. Clinical programs include MANTRA (Phase 3 in dedifferentiated liposarcoma), MANTRA-2 (Phase 2 in TP53 wildtype/MDM2-amplified solid tumors), and MANTRA-4 (Phase 1/2 with atezolizumab in CDKN2A loss, TP53 wildtype tumors).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Rain Oncology company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Viome Life Sciences
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Viome Life Sciences
2.2 - Growth funds investing in similar companies to Viome Life Sciences
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Viome Life Sciences
4.2 - Public trading comparable groups for Viome Life Sciences
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →